← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ENDOCRINE THERAPY › HORMONES AND RELATED AGENTS › Gonadotropin releasing hormone analogues
triptorelin
L02AE04
Forms & Strengths
- Injectable suspension, sustained-release: 3.75 mg, 11.25 mg, 22.5 mg
Adult Dosing
- Advanced prostate cancer: 3.75 mg IM monthly, or 11.25 mg IM every 3 months, or 22.5 mg IM every 6 months
Pediatric Dosing
- Central precocious puberty: 3.75 mg to 11.25 mg IM every 4 weeks based on weight and clinical response
Indications
- Palliative treatment of advanced prostate cancer
- Central precocious puberty in children
Mechanism of Action
- Potent agonist of gonadotropin-releasing hormone (GnRH) receptors
- Initial stimulation leads to transient surge in LH, FSH, and testosterone/estrogens
- Continuous chronic administration causes pituitary GnRH receptor downregulation, decreasing LH/FSH secretion and resulting in castrate levels of sex steroids
Contraindications
- Hypersensitivity to GnRH, GnRH agonist analogs, or components
- Pregnancy and lactation
Adverse Reactions
- Hot flashes and flushing
- Decreased libido and impotence
- Injection site reactions and pain
- Bone pain (initial flare phenomenon)
- Mood changes, depression, fatigue
- Decreased bone mineral density
Drug Interactions
- Drugs that prolong QT interval
- Agents that alter pituitary secretion of gonadotropins
Curated Content: Needs Vetting Before Put to Clinical Use